I don't believe the current investor should bail out the company but the company itself should use all the resources available to deal with current and future financial and R&D challenges.
They should capitalize on the recent rejuvenated interest from the retail sector. The activities and followers on Stocktwits have increased recently so if you have something to say/sell to individual/institutional investors then say and sell it to the retail sector preferably using reputable and well followed social media channels.
Much more frequent,transparent and direct communication with the market such as business updates by the management written or online conferences.
Cost cutting/control should be an ongoing process not only because of Marathon's requirements but also because of financial health and stability of the company which needs to have funds supporting the stage gated oncology trial. Among others reducing headcount including few from the board of director reallocating extra tasks to remaining staff, stop extravagant automatic bounces/ absurd option grants and reduce wages especially the C suite with multiple 6 and 7 figures salaries.
Increase sales by educating both patients and doctors about many recent medical benefits of specifically Egrifta, constantly looking for avenues to reduce and optimize the cost of sales( logistics,production facilities, remote /online communication with the targeted customers, strict performance standards among the sale force/MSLs ...).
Better and more frequent/vigilant surveillance of the oncology process followed by instant flexible response based on the results. Don't fall in love with the current protocol but be prepared for taking necessary actions in timely fashion.
The point is a capable and responsible approach can and should improve the financials and improve the odds for the sort1 platform.